Journal articles
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer
Abstract : This document provides a short summary of the GARNET trial which was published in JAMA Oncology in October 2020. At the end of this document, there are links to websites where you can find more information about this study. The trial enrolled adult participants with advanced solid tumors. This report is restricted to patients with a particular type of endometrial cancer that has a deficient mismatch repair (dMMR) status. Patients received a trial treatment called dostarlimab (also known by the brand name Jemperli). In the US, dostarlimab is approved as a single therapy in adult patients with dMMR recurrent or advanced endometrial cancer that has progressed on or after platinum-based chemotherapy. In the EU, dostarlimab is approved as a single therapy in adult patients with recurrent or advanced dMMR/microsatellite instability–high (MSI-H) endometrial cancer that has progressed on or after treatment with a platinum-containing regimen. The GARNET trial looked at dostarlimab given intravenously to patients with dMMR endometrial cancer from 7 countries. The trial showed that dostarlimab was successful in shrinking the tumor in 42% of these patients. In general, the percentage of participants who experienced medical problems (referred to as side effects) was low and within expectations for this type of treatment. ClinicalTrials.gov NCT number: NCT02715284 .
https://hal-amu.archives-ouvertes.fr/hal-03623657
Contributor : Jacques A Nunes Connect in order to contact the contributor
Submitted on : Tuesday, March 29, 2022 - 6:15:50 PM
Last modification on : Tuesday, April 12, 2022 - 3:19:15 AM
Contributor : Jacques A Nunes Connect in order to contact the contributor
Submitted on : Tuesday, March 29, 2022 - 6:15:50 PM
Last modification on : Tuesday, April 12, 2022 - 3:19:15 AM
Links full text
